Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 11/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4816411 | 0.85 | ABCG2 (0.52) | ACP1MAP4K4MEN1KMT2AMAOB | |
| SCHEMBL4816022 | 0.79 | ALDH1A1 (0.42) | ACP1EGFRERBB2MEN1NPC1 | |
| SCHEMBL4021555 | 0.78 | NT5E (0.48) | ACP1MAP4K4MAOB | |
| SCHEMBL4023370 | 0.76 | NT5E (0.49) | ACP1MAP4K4MAOB | |
| SCHEMBL4032492 | 0.74 | NT5E (0.45) | ACP1MAP4K4MEN1KMT2AMAOB | |
| SCHEMBL4826847 | 0.73 | MAP4K4 (0.46) | MAP4K4MEN1KMT2AMAOBTERT | |
| SCHEMBL4031373 | 0.72 | ABCG2 (0.52) | ACP1MAP4K4MEN1KMT2AMAOB | |
| SCHEMBL4028750 | 0.71 | ABCG2 (0.48) | ACP1MAP4K4MEN1KMT2AMAOB | |
| SCHEMBL4025363 | 0.71 | ABCG2 (0.48) | ACP1MAP4K4MEN1KMT2AMAOB | |
| SCHEMBL4823113 | 0.71 | ABCG2 (0.48) | ACP1MAP4K4MEN1KMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348340-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2008-03-25 | — | — | US | disclosed |
| US-20070129363-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129363-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | CACNA1B, CACNA1E, CACNA1G | ACP1 2923/4885EGFR 4475/4885ERBB2 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.